title: Activities of lipogenic enzymes in subcutaneous adipose tissue are not increased in patients with chronic kidney failure.
abstract: BACKGROUND
  Since renal replacement therapy has started to be a routine procedure in chronic kidney disease (CKD), patients no longer die of end-stage renal disease (ESRD). Today, patients with CKD live longer and the most important causes of morbidity and mortality in this group are cardiovascular events. Lipid abnormalities, such as hypertriglyceridemia (HT), are an important factor of high cardiovascular risk in this group. It is known that HT is partially caused by inhibition of lipolysis, but it is also postulated that increased lipogenesis is another cause of HT. Previous studies performed in our center has provided evidence that lipogenesis is increased in the animal model of ESRD.
  
  
  OBJECTIVE
  The aim of this study was to investigate the activities of lipogenic enzymes in the subcutaneous white adipose tissue in patients with CKD.
  
  
  METHODS
  The study was performed on 36 patients (17 women and 19 men). Patients with ESRD were divided into 2 groups: patients on conservative treatment in the prehemodialysis period (pre‑HD group, n = 18) and patients on maintenance hemodialysis (HD group, n = 18). The control group consisted of 22 patients without ESRD. The activities of lipogenic enzymes in the subcutaneous white adipose tissue (fatty acid synthase, adenosine triphosphate citrate lyase, malic enzyme, glucose‑6‑phosphate dehydrogenase, and 6‑phosphogluconate dehydrogenase) were assessed by spectrophotometry.
  
  
  RESULTS
  There were no statistically significant differences in the activities of lipogenic enzymes in a fat tissue sample between patients with ESRD and the control group.
  
  
  CONCLUSIONS
  The results did not confirm increased lipogenesis in patients with ESRD.
authors.affiliation: Department of Nephrology, Transplantology and Internal Medicine, Medical University of Gdańsk, Gdańsk, Poland. wwolyniec@wp.pl
authors.forename: Wojciech
authors.initials: W
authors.lastname: Wołyniec
authors.forename: Julian
authors.initials: J
authors.lastname: Swierczyński
authors.forename: Marek
authors.initials: M
authors.lastname: Szołkiewicz
authors.forename: Michał
authors.initials: M
authors.lastname: Chmielewski
authors.forename: Przemysław
authors.initials: P
authors.lastname: Rutkowski
authors.forename: Bolesław
authors.initials: B
authors.lastname: Rutkowski
mesh_terms: D000251:Adenosine Triphosphatases / Q000378:metabolism; D000328:Adult; D000368:Aged; D054890:Fatty Acid Synthase, Type I / Q000378:metabolism; D005260:Female; D005954:Glucosephosphate Dehydrogenase / Q000378:metabolism; D006801:Humans; D007676:Kidney Failure, Chronic / Q000201:enzymology*; D050155:Lipogenesis; D008291:Malate Dehydrogenase / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D009097:Multienzyme Complexes / Q000378:metabolism; D007652:Oxo-Acid-Lyases / Q000378:metabolism; D010734:Phosphogluconate Dehydrogenase / Q000378:metabolism; D050151:Subcutaneous Fat / Q000201:enzymology*
chemical_list: D009097:Multienzyme Complexes; D008291:Malate Dehydrogenase; C495394:malic enzyme 2; human; D010734:Phosphogluconate Dehydrogenase; D005954:Glucosephosphate Dehydrogenase; C518729:FASN protein, human; D054890:Fatty Acid Synthase, Type I; D000251:Adenosine Triphosphatases; D007652:Oxo-Acid-Lyases; C019909:citrate (pro-3S)-lyase